



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 55154

**Title:** Extremely rare case of successful treatment of metastatic ovarian undifferentiated carcinoma with high-dose combination cytotoxic chemotherapy: A case report

**Reviewer's code:** 03072151

**Position:** Editorial Board

**Academic degree:** MD, MSc

**Professional title:** Assistant Professor, Attending Doctor, Surgeon

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** South Korea

**Manuscript submission date:** 2020-03-03

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2020-07-05 06:29

**Reviewer performed review:** 2020-07-05 08:04

**Review time:** 1 Hour

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **SPECIFIC COMMENTS TO AUTHORS**

Dear editor and authors, The authors conducted a case report study of an extremely rare case of recurrent and inoperable metastatic ovarian mucinous anaplastic carcinoma, and reported their successful experience of using a high dose combination cytotoxic chemotherapy VIP (etoposide, ifosfamide, cisplatin) instead of the widely used paclitaxel and platinum in treating the patient. Please proofread the whole text. There are some minor syntax and grammatical errors throughout the manuscript, although the authors claimed that the manuscript was sent for English editing. The manuscript needs further language/grammar revision. For instance: Line 4: "...in early stage and it is favorable prognosis." should be better presented as "...in its early stage and has a favorable prognosis." Besides, I have the following concerns regarding the content of manuscript:

Did you send for a frozen section during the resection surgery? Why not a safe margin instead? Please explain more clearly the difficulties you were facing during the surgery to maintain a safe margin for the resection of the tumor. The patient was diagnosed with ovarian mucinous anaplastic carcinoma with sarcomatoid change, where the standard regimen commonly used for ovarian epithelial cancer (paclitaxel and platinum) was reported to have a poor response. Instead, the authors applied the high dose combined cytotoxic chemotherapy VIP regimen to target the sarcomatous component. Possible side effects of this regimen were already reported in the text. Are there any other chemotherapy regimens or palliative therapies available to be considered? Radiation therapy is occasionally used to treat ovarian cancer that has spread away. Please expand your discussion with other possible treatment modalities.



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 55154

**Title:** Extremely rare case of successful treatment of metastatic ovarian undifferentiated carcinoma with high-dose combination cytotoxic chemotherapy: A case report

**Reviewer's code:** 00722050

**Position:** Editorial Board

**Academic degree:** FRCP (C), MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Canada

**Author's Country/Territory:** South Korea

**Manuscript submission date:** 2020-03-03

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2020-07-05 00:55

**Reviewer performed review:** 2020-07-05 11:51

**Review time:** 10 Hours

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors have successfully treated a recurrent and inoperable case of ovarian mucinous anaplastic carcinoma only using high dose combination chemotherapy. The aggressive combination chemotherapy could be used as an new alternative chemotherapy regimen alternative to the widely used treatment option. This case is an educational case report that can help to treat these rare tumor occurrence. Very nice microphotographs, but please put the label of cytokeratins on the upper right corner of figure 2B. Also, specify which pan-cytokeratins or subtype of cytokeratins (clone, dilution, and company) have been used.



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 55154

**Title:** Extremely rare case of successful treatment of metastatic ovarian undifferentiated carcinoma with high-dose combination cytotoxic chemotherapy: A case report

**Reviewer's code:** 00722239

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** South Korea

**Manuscript submission date:** 2020-03-03

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2020-07-05 02:34

**Reviewer performed review:** 2020-07-07 07:30

**Review time:** 2 Days and 4 Hours

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors reported a case of rare ovarian cancer successfully treated by surgery for primary site and chemotherapy for recurrent tumor. Their diagnosis and usage of the term of "Ovarian mucinous anaplastic carcinoma" is quite improper. Anaplastic carcinoma is generally considered as "Carcinoma which shows no cytological or architectural features associated with more differentiated tumors". Therefore, the tumors showing mucinous differentiation never diagnose as anaplastic carcinoma. As the authors cited, previous reports used the diagnosis of "Anaplastic carcinoma arising in a mucinous tumour of the ovary" or "mucinous carcinoma of the ovary with mural nodules of anaplastic carcinoma". The authors should revise the manuscript using these appropriate terms. The authors should show gross figures and histological figures for mucinous tumor component. In discussion, first sentence, "Ovarian tumors with a mural nodule are rare" is wrong. Ovarian tumors with a mural nodule are common. Ovarian tumors with a mural nodule which composed of sarcomatous or anaplastic carcinoma are rare.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 55154

**Title:** Extremely rare case of successful treatment of metastatic ovarian undifferentiated carcinoma with high-dose combination cytotoxic chemotherapy: A case report

**Reviewer's code:** 03072151

**Position:** Editorial Board

**Academic degree:** MD, MSc

**Professional title:** Assistant Professor, Attending Doctor, Surgeon

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** South Korea

**Manuscript submission date:** 2020-03-03

**Reviewer chosen by:** Jin-Lei Wang

**Reviewer accepted review:** 2020-08-10 06:09

**Reviewer performed review:** 2020-08-10 06:42

**Review time:** 1 Hour

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

The authors have properly addressed the criticisms and I believe that the present manuscript is improved and acceptable for publication. Congratulations!